CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($) shares in Thousands, $ in Thousands	Total	Non-Designated Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Loss	Accumulated Other Comprehensive Loss
Balance, beginning of period at Dec. 31, 2018	$ (12,008)	$ 2	$ 202,355	$ (11,435)	$ (199,592)	$ (3,338)
Balance, beginning of period (in shares) at Dec. 31, 2018		22,912
Stock issued upon the exercise of stock options	744		744
Stock issued upon the exercise of stock options (in shares)		67
Restricted stock award and performance stock unit vesting (in shares)		270
Unrestricted common stock issued in lieu of cash bonus	576		576
Unrestricted common stock issued in lieu of cash bonus (in shares)		37
Stock-based compensation expense	1,220		1,220
Net loss	(544)				(544)
Other comprehensive income (loss)	213					213
Balance, end of period at Mar. 31, 2019	(9,799)	$ 2	204,895	(11,435)	(200,136)	(3,125)
Balance, end of period (in shares) at Mar. 31, 2019		23,286
Balance, beginning of period at Dec. 31, 2019	(16,192)	$ 2	210,846	(11,435)	(212,548)	(3,057)
Balance, beginning of period (in shares) at Dec. 31, 2019		23,667
Stock issued upon the exercise of stock options	42		42
Stock issued upon the exercise of stock options (in shares)		6
Restricted stock award and performance stock unit vesting (in shares)		299
Unrestricted common stock issued in lieu of cash bonus	1,322		1,322
Unrestricted common stock issued in lieu of cash bonus (in shares)		68
Stock-based compensation expense	1,998		1,998
Net loss	(6,181)				(6,181)
Cumulative effect adjustment - adoption of CECL | CECL	75				75
Other comprehensive income (loss)	(53)					(53)
Balance, end of period at Mar. 31, 2020	$ (18,989)	$ 2	$ 214,208	$ (11,435)	$ (218,654)	$ (3,110)
Balance, end of period (in shares) at Mar. 31, 2020		24,040